CLINICAL_TRIALS
trial_result
· 2021-07-13
Clinical Trial Update: Real World, Open Label, QOL Assessment of Peanut Immunotherapy AR101 in Children and Adolescents [Phase 3]
Summary
Phase 3 real-world, open-label study of AR101 for peanut allergy in children and adolescents; terminated with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Aimmune Therapeutics, Inc. | Conditions: Peanut Allergy | Phase 3 | Status: TERMINATED | Results posted: 2021-07-13